JP2016507569A - ラミブジン結晶塩 - Google Patents

ラミブジン結晶塩 Download PDF

Info

Publication number
JP2016507569A
JP2016507569A JP2015557055A JP2015557055A JP2016507569A JP 2016507569 A JP2016507569 A JP 2016507569A JP 2015557055 A JP2015557055 A JP 2015557055A JP 2015557055 A JP2015557055 A JP 2015557055A JP 2016507569 A JP2016507569 A JP 2016507569A
Authority
JP
Japan
Prior art keywords
lamivudine
crystalline
hydrochloride
sulfate
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015557055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507569A5 (enExample
Inventor
ショーン マーク ダルジール，
ショーン マーク ダルジール，
マーク マイケル メニング，
マーク マイケル メニング，
Original Assignee
トビラ セラピューティクス， インコーポレイテッド
トビラ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トビラ セラピューティクス， インコーポレイテッド, トビラ セラピューティクス， インコーポレイテッド filed Critical トビラ セラピューティクス， インコーポレイテッド
Publication of JP2016507569A publication Critical patent/JP2016507569A/ja
Publication of JP2016507569A5 publication Critical patent/JP2016507569A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015557055A 2013-02-07 2014-02-06 ラミブジン結晶塩 Pending JP2016507569A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762018P 2013-02-07 2013-02-07
US61/762,018 2013-02-07
PCT/US2014/015024 WO2014124092A2 (en) 2013-02-07 2014-02-06 Lamivudine salts

Publications (2)

Publication Number Publication Date
JP2016507569A true JP2016507569A (ja) 2016-03-10
JP2016507569A5 JP2016507569A5 (enExample) 2017-01-19

Family

ID=50151399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557055A Pending JP2016507569A (ja) 2013-02-07 2014-02-06 ラミブジン結晶塩

Country Status (5)

Country Link
US (1) US9688666B2 (enExample)
EP (1) EP2953945A2 (enExample)
JP (1) JP2016507569A (enExample)
CA (1) CA2898092A1 (enExample)
WO (1) WO2014124092A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898092A1 (en) 2013-02-07 2014-08-14 Tobira Therapeutics, Inc. Lamivudine salts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225069A (zh) * 2011-04-29 2011-10-26 陶珍珠 一种耐药性显著降低的药物组合物及其制备方法和其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288033B1 (en) * 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
CN1406233A (zh) * 2000-02-28 2003-03-26 拜尔公司 用于病毒性疾病的药物
CA2351049C (en) * 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
ES2547002T3 (es) * 2002-09-13 2015-09-30 Novartis Ag Beta-L-2' desoxinucleósidos para el tratamiento de cepas de VHB resistentes
AU2003277208A1 (en) * 2002-10-01 2004-04-23 Georgetown University Diagnostic for long term response of hbv carrier to 3tc therapy
CN1517347A (zh) * 2003-01-16 2004-08-04 北京昭衍新药研究中心 抗病毒核苷衍生物
TWI332402B (en) * 2003-12-19 2010-11-01 Ind Tech Res Inst An extract for treating hepatitis
ATE485292T1 (de) * 2006-04-18 2010-11-15 Lupin Ltd Neue kristalline form von lamivudin
KR20080086687A (ko) * 2007-03-23 2008-09-26 주식회사 파나진 라미부딘 내성 ｂ형 간염바이러스 검출을 위한 ρνα프로브, 키트 및 방법
WO2009031026A2 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel pharmaceutical compositions
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
WO2009069013A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Crystalline form i of lamivudine and its preparation
WO2010023676A2 (en) * 2008-09-01 2010-03-04 Hetero Research Foundation Process for preparing lamivudine polymorph form
US20110282046A1 (en) 2009-01-19 2011-11-17 Rama Shankar Process for preparation of cis-nucleoside derivative
WO2010137027A1 (en) * 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
BRPI0903664B8 (pt) * 2009-09-22 2021-05-25 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp método de obtenção de nova forma cristalina de lamivudina, seu sal cloridrato monoidratado, formulações farmacêuticas e seus usos
KR101961601B1 (ko) * 2009-11-16 2019-03-25 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US8796452B2 (en) * 2010-02-12 2014-08-05 Merck Sharp & Dohme Corp. Preparation of lamivudine form I
CN102167696B (zh) * 2010-02-25 2013-09-18 南京正大天晴制药有限公司 拉米夫定草酸盐及其制备方法
CN103282369A (zh) 2011-04-08 2013-09-04 劳乐斯实验室私营有限公司 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物
CA2835272A1 (en) * 2011-05-30 2012-12-06 Cipla Limited Pharmaceutical antiretroviral composition
JP2015509524A (ja) * 2012-03-05 2015-03-30 シプラ・リミテッド ラミブジン、フェスティナビルおよびネビラピンを含んでなる抗レトロウイルス医薬組成物
CA2898092A1 (en) * 2013-02-07 2014-08-14 Tobira Therapeutics, Inc. Lamivudine salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225069A (zh) * 2011-04-29 2011-10-26 陶珍珠 一种耐药性显著降低的药物组合物及其制备方法和其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELLENA JAVIER, CRYSTENGCOMM, vol. V14 N7, JPN5016002056, 2012, pages 2373 - 2376, ISSN: 0003791321 *
TATSUO MARUYAMA ET AL.: "Sequence-selective extraction of single-stranded DNA using DNA-functionalized reverse micelles", CHEMICAL COMMUNICATIONS, vol. 43, JPN7016002055, 21 November 2007 (2007-11-21), pages 4450 - 4452, ISSN: 0003791320 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0003791322 *

Also Published As

Publication number Publication date
US20150368232A1 (en) 2015-12-24
CA2898092A1 (en) 2014-08-14
WO2014124092A3 (en) 2014-10-23
EP2953945A2 (en) 2015-12-16
WO2014124092A2 (en) 2014-08-14
US9688666B2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
AU2015214182B2 (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP2753603B1 (en) Polymorphic form of pridopidine hydrochloride
EA034409B1 (ru) Способы получения кристаллического фенилацетата l-орнитина
US20240199585A1 (en) Solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
PT1710245E (pt) Forma cristalinade maleato de asenapina
US20230295121A1 (en) Solid forms of pralsetinib
CN103965116A (zh) 半5-氟胞嘧啶盐、其制备方法及应用
NZ590286A (en) Phosphate and sulphate salts of 6-{ 2-[1-(6-methyl-3-pyrazinyl)-4-piperidinyl]ethoxy} -3-ethoxy-1,2-benzisoxazole
JP2016507569A (ja) ラミブジン結晶塩
WO2025082550A2 (zh) N-(3-氟苯基)-6-(6,7-二甲氧基喹啉-4-氧基)-3,4-二氢喹啉-1(2h)-甲酰胺甲磺酸盐晶型及制备方法
BRPI0922736B1 (pt) Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste
WO2018086473A1 (zh) 阿普斯特共晶及其制备方法
JP2023531077A (ja) 化合物の塩、及び塩を含む医薬組成物
CN104955808A (zh) 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型
CN103408400A (zh) 一种肌醇晶体及其制备方法和用途
AU2024289011A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide
HK40103083A (zh) (3r)-n-[2-氰基-4-氟-3-(3-甲基-4-氧代-喹唑啉-6-基)氧基-苯基]-3-氟-吡咯烷-1-磺酰胺的新颖固体形式
WO2021154122A2 (ru) L-, U-модификации 5-хлор-N-({(5S)-2-оксо-3-[4-3-оксо-4-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида, сольват с диметилсульфоксидом, способы их получения, фармацевтические композиции на их основе, ингибирующие фактор Ха
CN105753868B (zh) 一种盐酸伐昔洛韦的半水合物及其制备方法
HK40069358A (en) Crystalline polymorphic substance of compound
HK40069359A (en) Crystalline polymorphic substance of compound
WO2025201325A1 (zh) 4-[3-(环丙基甲氧基)-4-(二氟甲氧基)苯乙基]吡啶-2(1h)-酮的固体形式及其制备方法
HK40071508A (en) Crystalline polymorphs of a compound
WO2015008973A1 (ko) 사포그릴레이트 염산염 결정형 ⅱ의 제조방법
EP2980091A1 (en) Novel hydrates of dolutegravir sodium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180508